Specific Supplementation in Counteracting the Adverse Effects of Oral Contraceptives
NCT ID: NCT07071389
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2018-01-08
2018-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
NCT03506399
Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects
NCT00901290
Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
NCT00362479
Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
NCT00206583
A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects
NCT03662516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Patients prescribed estroprogestinic oral contraceptive
Oral contraceptive
Patients in the study group receive daily dose of estroprogestinic oral contraceptive
Study group
Patients prescribed estroprogestinic oral contraceptive were treatedwith Zyxelle supplement
Zyxelle
Patients in the study group receive Zyxelle dietary supplement along with the oral contraceptive
Oral contraceptive
Patients in the study group receive daily dose of estroprogestinic oral contraceptive
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zyxelle
Patients in the study group receive Zyxelle dietary supplement along with the oral contraceptive
Oral contraceptive
Patients in the study group receive daily dose of estroprogestinic oral contraceptive
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Prescription for COC treatment
Exclusion Criteria
2. previous or existing breast pathologies;
3. hypertension;
4. obesity;
5. smoking habits;
6. cardiovascular disorders
18 Years
39 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lo.Li.Pharma s.r.l
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Studio Medico Anteo
Terni, TR, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.